K. A. Papp, “Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study”, J of Skin, vol. 3, p. S35, Nov. 2019.